ADGRL4抗体;ADGRL4 Antibody—艾普蒂 新品

The ADGRL4 antibody targets ADGRL4 (Adhesion G Protein-Coupled Receptor L4), also known as LPHN4. a member of the adhesion-GPCR family. These receptors are characterized by a large extracellular N-terminal region involved in cell-cell or cell-matrix interactions, a seven-transmembrane domain, and intracellular signaling motifs. ADGRL4 plays roles in cellular adhesion, signaling, and tissue development, with emerging implications in cancer biology, particularly in tumor angiogenesis and endothelial cell regulation. Studies suggest its overexpression in certain cancers, such as melanoma and colorectal cancer, where it may promote vascularization and metastasis. ADGRL4 antibodies are essential tools for detecting receptor expression, studying its functional mechanisms, and exploring therapeutic applications. They are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to analyze protein localization, signaling pathways, and interactions with ligands like fibronectin. Recent research also highlights ADGRL4 as a potential biomarker or therapeutic target for anti-angiogenic therapies. Antibodies against specific domains (e.g., extracellular or intracellular regions) enable investigations into receptor activation, cleavage, or downstream signaling. However, challenges remain in understanding its precise physiological roles and ligand specificity, necessitating further validation of antibody reliability across experimental models.